Newly Diagnosed T- Lymphoblastic LeukemiaStatus: open
[824258-5] Protocol AALL1231 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
Treatment for Pediatric Oncology - T Acute Lymphoblastic Leukemia
This randomized phase III trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma. Bortezomib may help reduce the number of leukemia or lymphoma cells by blocking some of the enzymes needed for cell growth. It may also help chemotherapy work better by making cancer cells more sensitive to the drugs. It is not yet known if giving standard chemotherapy with or without bortezomib is more effective in treating T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. IRB Number 15-260
SponsorsThis trial is sponsored by Children's Oncology Group.
Interested in Clinical Trial?
Providers Associated With This Trial
- Hamayun Imran, M.D.Pediatric Hematologist/OncologistProfessor of Pediatrics